검색
Neumora Therapeutics Inc
NMRA관심 목록에 추가
1.840USD
-0.130-6.60%
종가 05/15, 16:00（ET）시세는 15분 지연됩니다
340.92M시가총액
손실P/E TTM
자세한 내용은 Neumora Therapeutics Inc 회사
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Neumora Therapeutics Inc 정보
종목 코드 NMRA
회사 이름Neumora Therapeutics Inc
상장일Sep 15, 2023
CEOBerns (Paul L)
직원 수110
유형Ordinary Share
회계 연도 종료Sep 15
주소260 Arsenal Place, Suite 1
도시WATERTOWN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02472
전화18577600900
웹사이트https://neumoratx.com/
종목 코드 NMRA
상장일Sep 15, 2023
CEOBerns (Paul L)
Neumora Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Ms. Helen Rubinstein
Ms. Helen Rubinstein
IR Contact Officer
IR Contact Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Thu, May 14
마지막 업데이트: Thu, May 14
주주
주주 유형
주주
주주
비율
Amgen Inc
19.09%
ARCH Venture Partners
18.27%
Invus Public Equities Advisors, LLC
4.59%
Berns (Paul L)
4.16%
SB Global Advisers Ltd
3.47%
기타
50.43%
주주
주주
비율
Amgen Inc
19.09%
ARCH Venture Partners
18.27%
Invus Public Equities Advisors, LLC
4.59%
Berns (Paul L)
4.16%
SB Global Advisers Ltd
3.47%
기타
50.43%
주주 유형
주주
비율
Investment Advisor
21.86%
Venture Capital
19.33%
Corporation
19.09%
Hedge Fund
7.86%
Individual Investor
4.52%
Investment Advisor/Hedge Fund
2.61%
Endowment Fund
1.79%
Research Firm
1.37%
Pension Fund
0.12%
기타
21.45%
기관 주식 보유
마지막 업데이트: Wed, Apr 1
마지막 업데이트: Wed, Apr 1
보고 기간
기관 수
보유 주식
비율
변동
2026Q1
301
106.55M
57.52%
-16.54M
2025Q4
291
86.53M
52.51%
-28.54M
2025Q3
293
86.79M
53.64%
-40.47M
2025Q2
288
142.02M
87.70%
-25.57M
2025Q1
283
144.00M
90.43%
+12.16M
2024Q4
249
161.18M
99.54%
+45.20M
2024Q3
201
148.65M
93.66%
+40.67M
2024Q2
179
142.61M
90.03%
+47.65M
2024Q1
154
133.89M
85.01%
+50.39M
2023Q4
108
122.49M
78.90%
+50.97M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Amgen Inc
35.37M
19.43%
--
--
Apr 10, 2025
ARCH Venture Partners
33.85M
18.59%
+1.92M
+6.00%
Oct 27, 2025
Invus Public Equities Advisors, LLC
9.00M
4.94%
+2.71M
+43.08%
Feb 13, 2026
Berns (Paul L)
7.67M
4.21%
-9.82K
-0.13%
Feb 17, 2026
SB Global Advisers Ltd
6.43M
3.53%
-111.47K
-1.70%
Dec 31, 2025
MIC Capital Management UK LLP
4.46M
2.45%
--
--
Dec 31, 2025
Point72 Asset Management, L.P.
3.67M
2.02%
+3.67M
--
Dec 31, 2025
Millennium Management LLC
3.62M
1.99%
+1.61M
+80.08%
Dec 31, 2025
Fidelity Management & Research Company LLC
3.50M
1.92%
-3.46K
-0.10%
Dec 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Biotechnology ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0%
iShares US Small-Cap Equity Factor ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Schwab U.S. Broad Market ETF
0%
더 보기
Invesco Nasdaq Biotechnology ETF
비율0.05%
ProShares Ultra Nasdaq Biotechnology
비율0.04%
Invesco RAFI US 1500 Small-Mid ETF
비율0.02%
iShares Biotechnology ETF
비율0.02%
Schwab U.S. Small-Cap ETF
비율0.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
비율0%
iShares US Small-Cap Equity Factor ETF
비율0%
Virtus LifeSci Biotech Clinical Trials ETF
비율0%
Fidelity MSCI Health Care Index ETF
비율0%
Schwab U.S. Broad Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
